CureVac to Showcase Data at 12th International mRNA Health Conference

CureVac N.V., a biopharmaceutical company based in Germany, will present at the 12th International mRNA Health Conference held in Boston from November 12-14, 2024. The company will share new data through two oral presentations and four posters. Key findings from the Phase 1 CVGBM cancer vaccine study in glioblastoma patients will be revealed, showcasing the vaccine's ability to induce specific T-cell responses in 77% of patients, with 84% being newly generated.

Another presentation will discuss CureVac's advancements in lipid nanoparticle (LNP) delivery systems. The posters will highlight enhancements in their mRNA platform and reveal targets for future development, emphasizing the platform's potential in areas like oncology and infectious diseases.

Dr. Myriam Mendila, Chief Scientific Officer, expressed the company's dedication to expanding mRNA applications across different therapeutic areas. These sessions confirm CureVac's ongoing innovation and commitment to advancing mRNA technology.